识别预测2型糖尿病肾功能快速下降的新型循环生物标志物:Fremantle糖尿病研究II期
在Fremantle糖尿病研究II期345例社区2型糖尿病患者中,采用质谱法检测基线血浆生物标志物,评估其预测4年随访期间eGFR快速下降轨迹的能力。调整临床预测因素后,apoA4、CD5L和C1QB独立预测快速下降,并改善模型性能、区分度和重分类;这些标志物及IBP3也有助于预测其他eGFR快速下降指标。
要点
- apoA4、CD5L和C1QB独立预测eGFR快速下降轨迹,并改善模型性能、区分度和重分类。
- 这些生物标志物及IBP3有助于预测其他eGFR快速下降指标。
- 新发现的生物标志物可能独立于已知临床危险因素改善肾功能快速下降的预测。
核心结论
- 本研究识别出新型血浆生物标志物(apoA4、CD5L、C1QB和IBP3),可能独立于已知临床危险因素改善2型糖尿病肾功能快速下降的预测。
研究设计与样本
- 研究纳入Fremantle糖尿病研究II期345例社区基础患者(平均年龄67.0岁,51.9%为男性),采用质谱法测量基线生物标志物。
- 采用多元逻辑回归确定4年随访期间基于半参数组基模型定义的eGFR快速下降轨迹的临床预测因素,并评估每种生物标志物的增量获益。
主要发现
- 基于eGFR轨迹分析,35例参与者(10.1%)被定义为「快速下降者」(平均下降2.9 mL/min/1.73 m²/年)。
- 调整临床预测因素后,apoA4、CD5L和C1QB独立预测快速下降,比值比分别为2.40(95%CI 1.24-4.61)、0.52(0.29-0.93)和2.41(1.14-5.11)。
- 这些生物标志物改善模型性能和拟合(P < 0.001)、区分度(曲线下面积0.75-0.82,P = 0.039)和重分类(净重分类指数0.76 [0.63-0.89];综合判别改善6.3% [2.1-10.4%])。
- 这些生物标志物及IBP3有助于改善预测其他eGFR快速下降指标的模型性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the ability of plasma apolipoprotein (apo) A-IV (apoA4), apo C-III, CD5 antigen-like (CD5L), complement C1q subcomponent subunit B (C1QB), complement factor H-related protein 2, and insulin-like growth factor binding protein 3 (IBP3) to predict rapid decline in estimated glomerular filtration rate (eGFR) in type 2 diabetes. RESEARCH DESIGN AND METHODS: Mass spectrometry was used to measure baseline biomarkers in 345 community-based patients (mean age 67.0 years, 51.9% males) from the Fremantle Diabetes Study Phase II (FDS2). Multiple logistic regression was used to determine clinical predictors of rapid eGFR decline trajectory defined by semiparametric group-based modeling over a 4-year follow-up period. The incremental benefit of each biomarker was then assessed. Similar analyses were performed for a ≥30% eGFR fall, incident chronic kidney disease (eGFR <60 mL/min/1.73 m2), and eGFR decline of ≥5 mL/min/1.73 m2/year. RESULTS: Based on eGFR trajectory analysis, 35 participants (10.1%) were defined as "rapid decliners" (mean decrease 2.9 mL/min/1.73 m2/year). After adjustment for clinical predictors, apoA4, CD5L, and C1QB independently predicted rapid decline (odds ratio 2.40 [95% CI 1.24-4.61], 0.52 [0.29-0.93], and 2.41 [1.14-5.11], respectively) and improved model performance and fit (P < 0.001), discrimination (area under the curve 0.75-0.82, P = 0.039), and reclassification (net reclassification index 0.76 [0.63-0.89]; integrated discrimination improvement 6.3% [2.1-10.4%]). These biomarkers and IBP3 contributed to improved model performance in predicting other indices of rapid eGFR decline. CONCLUSIONS: The current study has identified novel plasma biomarkers (apoA4, CD5L, C1QB, and IBP3) that may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in type 2 diabetes.
引用
- Peters KE, Davis WA, Ito J, et al. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. 2017. PMID: 28851702. doi:10.2337/dc17-0911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。